Background


Antiretroviral therapy (ART) can greatly reduce the risk of HIV transmission from an infected person (treatment as prevention, TasP) and may prevent an uninfected person from becoming infected (pre-exposure prophylaxis, PrEP). However, it remains unclear what proportions of HIV-infected and uninfected people need to receive ART to control local HIV epidemics.



Getting to Zero


This tool aims to provide an intuitive and flexible way to determine optimal targets of TasP and PrEP coverage in local settings. Users can set up the demographic characteristics (HIV prevalence, total population size) and adjust other variables according to their own local settings.

After defining these input variables, users can evaluate the impact of TasP and PrEP over a defined period of time. Of note, we have set the efficacy of TasP and PrEP to 80 and 70% respectively.
The output variable include the number of new HIV infection over a given period of time with or without any TasP and/or PrEP intervention and a crude estimate of the cumulative cost of these interventions.

We hope this could help public health and policy makers in their strategies to control local HIV epidemics and we are expecting users’ feedback for further development.



Questions?


For any questions or comments, you can contact us:



This work is supported by funds and grants from the following: the California HIV/AIDS Research Program (CHRP) Grant F13SD321, the Department of Veterans Affairs and grants from the National Institutes of Health: NIH Grants including AI106039, AI43638, AI074621, AI108351, AI036214, AI093163, AI100665, DA034978, AI036214; the Bettencourt-Schueller Foundation; the Max Kade Foundation, New York (Max Kade Postdoctoral Research grant); and the James B. Pendleton Charitable Trust.